Saccharomyces boulardii and Increased Helicobacter pylori Eradication Rate

Doses used in studies

mg/day: 500–1,000 (median 750, IQR 625–875) — 2 studies

Time to effect

Median: 10 days · IQR 10 days–10 days · Range 10 days–10 days — Reported in 2 of 2 studies

Safety in these studies

adverse events (overall)No significant difference
S. boulardii reduced the frequency of adverse events ( P = 0.033) in 14-day regimen, particularly treatment-associated diarrhea ( P = 0.032). However, after the adjustment to control Type I error, results lost their significance.
from: Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and
diarrheaNo significant difference
S. boulardii reduced the frequency of adverse events ( P = 0.033) in 14-day regimen, particularly treatment-associated diarrhea ( P = 0.032). However, after the adjustment to control Type I error, results lost their significance.
from: Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and
Overall tolerabilityReported
patients in the experimental group experienced a significantly lower overall incidence of AEs (17.0% vs. 55.7%; p < 0.001)
from: Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infecti
antibiotic-associated diarrheaReported2.0% vs. 46.4%
the incidence of antibiotic-associated diarrhea (2.0% vs. 46.4%; P = 0.02)
from: Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infecti

2 of 2 papersPopulation:

Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation.
- 2023-11-06
- RCT · n = 404
- European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 33(3)
- - Olga Sjomina
  - Inese Poļaka
  - Jekaterina Suhorukova
  - Reinis Vangravs
  - Sergejs Paršutins
  - Viktoria Knaze
  - Jin Young Park
  - Rolando Herrero
  - Raul Murillo
  - Mārcis Leja
- PubMed: 37942999
- DOI: 10.1097/cej.0000000000000858
2 Insights on
- Increased Helicobacter pylori Eradication Rate
- High evidence
- Large Human Trial
- Adults
Intention-to-treat analysis revealed higher eradication rates for 10-day probiotic treatment (70.8% vs. 54.6%, P = 0.022), but not for 14-day. Probiotic subgroups combined showed non-significantly higher efficacy in per-protocol analysis (90.6% vs. 85.0%, P = 0.183).
Effect
Neutral
Effect size
Small
Significant
No
Dose
500 mg BID
Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.
- 2019-01-29
- RCT · n = 199
- European journal of clinical pharmacology 75(5)
- - Hassan Seddik
  - Hanae Boutallaka
  - Ilham Elkoti
  - Fouad Nejjari
  - Reda Berraida
  - Sanaa Berrag
  - Khaoula Loubaris
  - Sara Sentissi
  - Ahmed Benkirane
- PubMed: 30694338
- DOI: 10.1007/s00228-019-02625-0
1 Insight on
- Increased Helicobacter pylori Eradication Rate
- High evidence
- Large Human Trial
- Clinical
The H. pylori eradication rate was higher in the experimental group than the control group (86.0% vs. 74.7%; P = 0.02).
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
250 mg twice daily

Saccharomyces boulardii and Increased Helicobacter pylori Eradication Rate

Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation.

Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.